Pfizer’s potential antiviral Paxlovid reduces 89% risk of severe Covid-19
Pfizer announced that its investigational Covid-19 oral antiviral candidate, Paxlovid, has significantly reduced hospitalisation and death, in an interim analysis of the Phase 2/3 EPIC-HR study. The primary